ResearcherEssen University HospitalNo recent work listed
Max Ernst Scheulen
Matched on OpenAlex author ID A5107233200. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper
Papers 3
- A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European… Co-author DOI 10.1016/j.ejca.2014.10.010↗
- Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pa… Co-author DOI 10.1007/s10637-010-9619-8↗
- Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). Last author DOI 10.1007/s10637-011-9665-x↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lothar Bergmann · 2 shared papers, 2012–2015 · strength 0.07
- Paper A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cance… DOI 10.1016/j.ejca.2014.10.010↗
- Paper Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). DOI 10.1007/s10637-011-9665-x↗
- Beate S. Schultheis · 2 shared papers, 2012 · strength 0.06
- Paper Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). DOI 10.1007/s10637-011-9665-x↗
- Paper Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patient… DOI 10.1007/s10637-010-9619-8↗
- Dirk Strumberg · 2 shared papers, 2012 · strength 0.06
- Paper Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group). DOI 10.1007/s10637-011-9665-x↗
- Paper Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patient… DOI 10.1007/s10637-010-9619-8↗
- Heike Richly · 1 shared paper, 2015 · strength 0.04
- Bernhard Josef Wormann · 1 shared paper, 2015 · strength 0.04
- Klaus B. Mross · 1 shared paper, 2012 · strength 0.03
- Florian Lordick · 1 shared paper, 2012 · strength 0.03
- Norbert Walter Marschner · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.